3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myeloid, Acute
12
Multiple Myeloma
11
Recurrence
8
Lymphoma, Large B-Cell, Diffuse
4
Sarcoma
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Endometrial Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, B-Cell
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Interventions
COVID-19 Vaccines
4
Blood Specimen Collection
4
Surveys and Questionnaires
3
Standard of Care
3
2019-nCoV Vaccine mRNA-1273
3
Pandemic Preparedness
2
sotrovimab
1
sinovac COVID-19 vaccine
1
selinexor
1
regorafenib
1
proxalutamide
1
monalizumab
1
lenzilumab
1
ciclesonide
1
bemcentinib
1
avdoralimab
1
acalabrutinib
1
XAV-19
1
Surgical Procedures, Operative
1
Sperm Count
1
Specimen Handling
1
Sorafenib
1
Sodium Chloride
1
Rabeprazole
1
Patient Reported Outcome Measures
1
Observation
1
Nutritional Status
1
Niclosamide
1
Meopa
1
Mastectomy, Segmental
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
COVID-19
×
selinexor
×
Clear all
NCT04534725
2023-08-24
C-SMART
Peter MacCallum Cancer Centre, Australia
Phase 3
Completed
441 enrolled